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Abstract 
 
Anthracyclines are potent cytostatic drugs the correct dosage of which is critical to aviod 
possible cardiac side effects. ABCC1 (MRP1) is expressed in the heart and takes part in the 
detoxification and protection of the cells from toxic effects of xenobiotics, including 
anthracyclines. Our objective was to search for associations between left ventricular function and 
single nucleotide polymorphisms of the ABCC1 gene in children who received anthracycline 
chemotherapy. We analyzed data of 235 pediatric patients with acute lymphoblastic leukemia. 
Patients were followed up by echocardiography (median follow up 6.3 years). Nine 
polymorphisms in the ABCC1 gene were genotyped. The ABCC1 rs3743527TT genotype and 
rs3743527TT-rs246221TC/TT genotype combination were found to be associated with lower left 
ventricular fractional shortening (LVFS) after chemotherapy. Our results suggest that genetic 
variants in the ABCC1 gene could influence anthracycline induced left ventricular dysfunction. 
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1. Introduction and background 
 
Childhood acute lymphoblastic leukemia (ALL) is cured in approximately 80-90% of the 
patients, but a significant number of survivors suffer from chemotherapy-induced side effects 
(Mody et al., 2008). These can appear during the treatment or become clinically evident years 
after the end of the therapy. Follow-up studies indicate that survivors of childhood leukemia 
often have cardiac problems as late side effects of the chemotherapy (Shankar et al., 2008; 
Mulrooney et al., 2009). These can be due to the most cardiotoxic anthracyclines but other drugs 
applied in the chemotherapy regimen can also damage the heart (Viale and Yamamoto, 2008). 
Anthracyclines such as doxorubicin and daunorubicin are highly effective antineoplastic drugs 
and used in a wide range of cancers (Johnson and Richardson, 1998). Anthracycline-induced 
cardiotoxicity can be divided into three types. Acute anthracycline-induced cardiotoxicity occurs 
during treatment, often immediately after the first dose of anthracycline has been administered. 
In contrast early onset chronic progressive anthracycline-induced cardiotoxicity presents within 1 
year after anthracycline administration and late onset chronic progressive cardiotoxicity develops 
years or even decades after treatment (Lipshultz et al., 2008). Anthracycline induced 
cardiotoxicity can be a mild, transient condition, caracterised by asymptomatic 
electrocardiographic changes, e.g., arrhythmias. More severe toxicities are left ventricular (LV) 
dysfunction, decreased exercise capacity, decreased left ventricular fractional shortening 
(LVFS), late onset cardiomyopathy, congestive heart failure. Heart dysfunction is associated 
with cardiomyocyte loss, LV wall thinning, and LV dilation (Wojtacki et al., 2000; Adams and 
Lipshultz, 2005; Iarussi et al., 2005). 
Late onset anthracycline-induced cardiotoxicity is far the most frequent cardiac consequence of 
the therapy. In a study with 115 survivors of childhood ALL several patients showed abnormal 
LV structure or function years after anthracycline treatment, while early onset anthracycline-
induced cardiotoxicity was usually experienced only in a few patients (Lipshultz et al., 2005). 
Subclinical reduction of heart function during or right after therapy might indicate increased 
susceptibility to late onset cardiomyopathy (Kremer et al., 2002; Scully and Lipshultz, 2007). 
Several risk factors for cardiotoxicity have been identified, including age at treatment (below 4 
years), concomitant therapy (irradiation and other antineoplastic drugs), gender (female) and 
cumulative dose of the drug. Nevertheless, the fact that there is no safe dose of anthracyclines 
and the wide interpatient variability in the time and seriousness of this adverse effect suggest that 
genetic background is a major determinant of drug response and toxicity (Lipshultz, Alvarez, 
2008). 
ATP-binding cassette (ABC) transporters have an important role in the protection of the body 
against xenobiotics (Borst et al., 2000; Sparreboom et al., 2003). These membrane-localized 
efflux pumps export a wide range of chemotherapeutic agents using the energy of ATP 
hydrolysis. ABC transporters have been found to be expressed in the heart and some of them 
have anthracyclines among their substrates (Couture et al., 2007). The ABCC1 (ATP-binding 
cassette, sub-family C, member 1 also denoted as MRP1: multidrug 
resistance-associated protein 1) transporter was first described in a doxorubicin resistant cell line 
and is expressed ubiquitously in the body. Tissues showing the highest level of ABCC1 
expression include the heart, lung, testis, kidney, and placenta. ABCC1 participates in 
detoxification, protects the cells from toxic effects of xenobiotics, and is also involved in the 
defense mechanisms against oxidative stress (Bakos and Homolya, 2007). ABCC1 expression 
was shown to be increased after doxorubicin treatment in cardiac tissue of mice (Jungsuwadee et 
 4
al., 2009) and experiments with Abcc1 knockout mice demonstrated an important role of this 
protein in the efflux of drugs from the heart. Finally several studies indicated that ABCC1 gene 
polymorphisms can influence the function of the transporter (Kerb et al., 2001). 
In this study our objective was to examine potential associations between subclinical reduction 
of cardiac function and the genetic background of childhood ALL patients investigating 
polymorphisms in the ABCC1 covering all haplotype blocks in this gene in order to gain more 
understanding on the genetic background of the anthracycline cardiotoxicity. 
 
 
2. Patients and methods 
2. 1. Study population and definitions 
 
We collected DNA retrospectively from children with ALL who underwent chemotherapy 
between 1990 and 2002, aged 1–18 years at diagnosis, treated according to the ALL Berlin–
Frankfurt–Münster (BFM) 90 or 95 study protocols in 6 Hungarian pediatric oncology centers. 
We included 235 children in the analysis. Characteristics of the study population are shown in 
Table 1. According to the data of the Hungarian Paediatric Cancer Registry, 337 cases were 
diagnosed with ALL in these hospitals during the same period who survived at least until the end 
of chemotherapy (Table 1). As seen, our cohort represents 70% of all cases. There is no 
difference in the distribution of the characteristics of the patients between the two groups. 
Informed consent was requested from the parents of patients. The study was approved by the 
Ethics Committee of the Hungarian Medical Research Council. 
The patients were followed up by echocardiography (ECHO) to assess left ventricular function 
by measuring left ventricular end-diastolic-dimension (LVEDD) and left ventricular end-systolic 
dimension (LVESD). Left ventricular fractional shortening (LVFS) was calculated from these 
two data: LVFS % = (LVEDD-LVESD)/LVEDD*100%. We analyzed the LVFS at three time 
points. First at the time of diagnosis, second at the end of the treatment that is at median 2.0 
years after diagnosis, while the third data point was determined at the time of the latest follow 
up. ECHO was performed with varying frequency at the different centers so LVFS data were not 
present in all time points of all the children. In the case of seven patients with relapsed leukemia, 
we included two separate “latest” datasets. These are the last ECHO results before starting 
relapse chemotherapy and the latest after relapse, featured by different cumulative anthracycline 
doses, respectively. 
The chemotherapy regimen included repeated doses of intravenous vincristine, L-asparaginase, 
daunorubicin, doxorubicin, methotrexate, cyclophosphamide, cytosine arabinoside, oral 
prednisone, dexamethasone, mercaptopurine, thioguanine, intrathecal methotrexate, intrathecal 
prednisone and ifosfamide (the latter only patients with high risk leukemia). The protocol in low 
risk and medium risk arms differed only in the number of anthracycline doses, the cumulative 
anthracycline doses were between 180-300 mg/m2. The high-risk arm differed considerably from 
the low risk and medium risk arms in terms of the applied therapy dosage. 
 
2.2. Laboratory methods 
 
DNA was extracted from peripheral blood taken in remission (n=206) from the survivors. DNA 
was obtained from bone marrow smears (n=19), from neonatal Guthrie spots (n=4) or from 
stored buffy coats (n=6) from patients who deceased before sample collection was carried out. 
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We extracted genomic DNA from blood using the QIAmpBlood DNA Maxi Kit (Qiagen, 
Hilden, Germany) according to the manufacturers’ instructions; from smears and from 
lymphocytes with HighPure PCR Template PreparationKit (Roche Diagnostics, Roche Applied 
Science, Mannheim, Germany) with minor alterations (see online Supplementary data) and from 
Guthrie spots using Chelex 100 reagent (Bio-Rad Laboratories, München, Germany). 
SNPs (single nucleotide polymorphism) were selected prioritized on the basis of their estimated 
functionality in this order: non-synonymous SNPs, SNPs in promoter and 3’ UTR region, 
synonymous SNPs and intronic SNPs. Our goal was to cover every haplotype block in the gene 
defined by the Haploview 4.1 software (http://www.broad.mit.edu/mpg/haploview/) (Barrett et 
al., 2005) with one or two SNPs. Detailed information on the selected SNPs is shown in Table 2. 
The ABCC1 rs45511401 genotypes were determined by multiplex single base extension using a 
SNaPshot Multiplex Kit (Applied Biosystems, Warrington, UK) followed by minisequencing on 
an ABI 310 genetic analyzer (Applied Biosystems). All other ABCC1 SNPs were genotyped 
using the GenomeLab SNPstream genotyping platform (Beckman Coulter, Krefeld, Germany) 
according to the manufacturer's instructions. Detailed description of these procedures can be 
found in the online Supplementary data. 
 
2.3. Statistical analysis 
 
Allele frequencies were calculated by allele counting. Hardy-Weinberg equilibrium (HWE) was 
tested by using an on-line software (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl, 
significant violation of HWE was considered if p< 0.01). We performed the statistical analysis to 
assess the effect of the genetic background on cardiac parameters with and multi-adjusted 
general linear model procedures. The multi-adjusted models included the following potential 
confounders: gender (male - female), age at the time of diagnosis (years), clinical center (6 
centers), total anthracycline dose (mg/m2), dexrazoxane usage (yes-no), and chemotherapy 
protocol (ALL BFM 90 - ALL BFM 95). Regarding the data at the time of diagnosis, the multi-
adjusted models included only gender, age at the time of diagnosis, clinical center and 
chemotherapy protocol. We analyzed the three genotype groups separately when the number of 
patients was sufficient in each group. 
Alpha levels of p<0.005, that is 0.05 after Bonferroni correction considering multiple testing for 
9 SNPs, were considered as significant. The analyses were performed using the SPSS 15.1 
(SPSS Inc., Chicago, IL, USA) and MedCalc 10.0.2 (MedCalc Software, Mariakerke, Belgium) 
software. 
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3. Results 
3.1. Study population and allele frequencies 
 
The characteristics of the study population are shown in Table 1. We performed genotyping for 
nine SNPs in ABCC1 gene. The positions of the investigated SNPs in the gene can be seen in 
Figure 1. Minor allelic frequencies are shown in Table 2. Genotype distributions were in Hardy-
Weinberg equilibrium (Table 2). 
 
3.2. The effect of genotypes on LVFS 
With the help of nine SNPs in the ABCC1 gene, we investigated whether these polymorphisms 
influence the cardiac functions of children with ALL after anthracycline therapy. The left 
ventricular fractional shortening (LVFS) of the patients were measured to estimate their cardiac 
function. 
There were no significant differences in the LVFS in the genotype groups at the time of 
diagnosis (Table 2; LVFS dg.). At later time points however, LVFS was found to be influenced 
by the ABCC1 rs246221 and rs3743527 polymorphisms. The ABCC1 rs3743527TT genotype 
group had decreased LVFS at the end of treatment echocardiography (34.0%) compared to 
patients with CC (39.5%) or CT (39.3%) genotype (p=0.001; Table 2 and Figure 2). LVFS was 
35.3%, 38.9% and 38.7% at the time of the latest echocardiography of the patients with TT, CT 
and CC genotypes, respectively, although due to the low number of patients being homozygote 
for the rare allele, this difference was not statistically significant. 
Further, we found an association between harboring the rs246221 T allele and LVFS at the time 
of the latest echocardiography (6.6 ± 2.7 years after the diagnosis). Patients with TC and TT 
genotype displayed reduced LVFS (38.4% and 38.5%) compared to patients with CC 40.7%, 
which was, however, only nominally significant (p=0.027; Table 2 and Figure 2).   
Among the clinical factors included in the analysis of LVFS, the age at the time of diagnosis, 
clinical center, chemotherapy protocol were found to be significant cofactors, while gender, total 
anthracycline dose, dexrazoxane usage were not (data not shown). In case of the two significant 
SNPs, none of these parameters influenced the effect of the genotypes. 
 
3. 2. The effect of genotype combinations on LVFS 
 
We analyzed the effect of genotype combinations on the LVFS. Patients harboring the 
rs3743527TT and rs246221TC or TT genotypes (group2) did not differ in their mean LVFS 
before chemotherapy from the patients with other genotypes (group1). However, after the 
chemotherapy the mean LVFS was significantly lower in patients with the TT-TC/TT genotype 
combination (34.0%) compared to other patients (39.4%) (p=0.001) (Table 3 and Figure 3). 
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4. Discussion 
 
Childhood acute lymphoblastic leukemia is highly curable today but the survivors may suffer 
from severe late side effects of the chemotherapy. One of the most important late adverse effects 
is anthracycline cardiotoxicity. The development and progression of this toxicity varies between 
patients, which suggests that drug toxicity might be influenced by genetic background. The 
patients survive for decades so it is particulary important to prevent these late side effects of the 
therapy, to identify early markers of these late problems and to identify patients with elevated 
susceblibility to development of late cardiac problems. In our study, we examined the association 
of genetic polymorphisms in the ABCC1 gene with left ventricular function after chemotherapy.  
We found that patients with the ABCC1 genotype rs3743527TT had reduced left ventricular 
fractional shortening (LVFS) at the end of the treatment. Moreover the genotype combination 
TT-TC/TT (rs3743527-rs246221) was associated with decreased LVFS.  
Possible limitations of or these findings are patients who died before the period of sample 
collection are underrepresented in our cohort. However, in our opininon this is not a relevant bias 
as late effects only manifest and have relevance in survivors. Furthermore, according to the data 
stored at the Hungarian Paediatric Cancer Registry, these patients did not die due to cardiac-
related events, thus these limitations are insufficient to question the results of our study. 
So far, there has been only one study in the literature published by Wojnowski et al., examining 
the role of ABC-transporters in anthracycline-induced cardiotoxicity (Wojnowski et al., 2005), in 
which 206 single nucleotide polymorphisms were examined in 82 genes comparing 87 Caucasian 
patients with non-Hodgkin lymphoma (NHL) experiencing cardiac problems with 363 NHL 
patients without any cardiac malfunction. 
The study found an association between chronic anthracycline-induced cardiotoxicity (ACT) and 
a polymorphism in the NAD(P)H oxidase subunit NFC4 (rs1883112), and between acute ACT 
and the NAD(P)H oxidase subunits CYBA (rs4673) and RAC2 (rs13058338); the ABC-
transporter ABCC1 Gly671Val variant (which is rs45511401) and the Val1188Glu - Cys1515Tyr 
(rs8187694-rs8187710) haplotype of the ABCC2 gene. 
Interestingly, in our study, we did not find an association between ABCC1 rs45511401 and 
reduced LVFS a fact that must be interpreted carefully, as there were differences in the 
chemotherapy protocols and the age of the study populations; and also because this SNP has a 
low minor allele frequency, which, together with the investigated number of patients makes this 
comparison under-powered. In addition, Wojnowski et al. defined the acute anthracycline-
induced cardiotoxicity with parameters we did not analyze. They defined cardiotoxicity on the 
basis of the following criteria: cases of arrhythmia, myocarditis, pericarditis, and acute heart 
failure as acute anthracycline-induced cardiotoxicity and the reduction of the ejection fraction 
<50%, or of the fractional shortening <25% was classified as chronic anthracycline-induced 
cardiotoxicity. We did not analyze their first three parameters regarding acute cardiotoxicity and 
we had only one patient with fractional shortening <25%. They found no association with 
ABCC1 rs45511401 and chronic anthracycline-induced cardiotoxicity which is similar to our 
study as we examined the reduction in left ventricular fractional shortening. In summary the 
important similarity between the two results is that both studies found association between 
cardiac problems and ABCC1 gene variations. Naturally for a more decisive statement, both 
studies ought to be replicated on independent and larger populations with similar study designs 
and with more SNPs in the ABCC1 gene involved in the analysis. 
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The ABCC1 transporter is important in the protection of the cell from distinct types of chemical 
stress. In most polarized cells, it is localized in the basolateral membrane, contralateral to the 
other ABC-transporters involved in the detoxification. This suggests that the main role of 
ABCC1 is the protection of the cells against xenobiotics (Bakos and Homolya, 2007). The 
anthracycline doxorubicin does not require any transporter to enter the cell, thus a sufficient 
efflux of this drug is very important in order to protect the cell (Borst, Evers, 2000). This fact is 
in agreement with our observation regarding the role of ABCC1 in the protection of 
cardiomyocytes. 
Also the ABCC1 transporter plays an important role in oxidative stress. It is involved in the 
maintenance of sufficient levels of glutathione, which is necessary for the defense against 
reactive oxygen species. Moreover, ABCC1 also requires glutathione for transport of 
anthracyclines (Borst, Evers, 2000; Kruh and Belinsky, 2003; Bakos and Homolya, 2007), which 
can also influence the response in oxidative stress induced by anthracyclines (Wojtacki, 
Lewicka-Nowak, 2000). 
In this present study, two SNPs, rs3743527 and rs246221 were found to influence the cardiac 
function after anthracycline treatment. Unfortunately, there is no data on the potential function of 
these SNPs. There are studies investigating the role of other known ABCC1 SNPs but not of 
these (Wang et al., 2006; Huang, 2007). Rs246221 is an exonic synonymous polymorphism, 
which does not influence the amino acid sequence. It is located in the linker region of the 
ABCC1. The rs3743527 SNP is located in the 3’untranslated region (UTR) of the ABCC1 gene. 
In the literature, there is only one study involving this SNP. Studying the susceptibility to lung 
cancer in Chinese patients Wang et al. investigated SNPs located in the 3'UTR of ABCB1 and 
ABCC1, including rs3743527. They found no association with ABCC1 rs3743527, but with 
ABCC1 rs212090 and ABCB1 rs3842. The ABCC1 rs212090 is only 300 bp distance away from 
rs3743527 (Wang et al., 2009). 
Further studies are important to reveal the exact role of these polymorphisms. Haplotype analysis 
may be useful to discover possible linked functional SNPs, because maybe not these but others in 
the same haplotype block influence the function of ABCC1. Also possible is the existence of 
some, yet unknown regulatory elements in this region, that could be affected by this SNP. 
According to the miRDB microRNA database (http://mirdb.org/miRDB/ ) there are predicted 
hsa-miR-185, hsa-miR-548o and hsa-miR-1254 binding sites in a 500bp region around 
rs3743527, which might have regulatory roles. Other polymorphisms in the same haplotype 
block with rs3743527 can influence the binding sequence of the regulatory elements. The 
ENCODE project (Birney et al., 2007) identified regulatory sites in the genome also in the 
proximity of SNPs in the ABCC1 gene. There are predicted transcription factor binding sites near 
rs3743527 and rs246221. The CTCF transcription factor binds 1235bp downstream from 
rs3743527, the BAF155 binds to 893bp downstream from rs246221. DNase hypersensitivity 
assays also show regulatory regions within 3000bp to these SNPs. 
In our study the anthracycline dose applied did not influence LVFS. This is probably because the 
dose range was relatively narrow (180-240mg/m2) in approximately 80% of the samples of the 
cohort. 
The threshold for LVFS associated with left ventricular systolic dysfunction is LVFS < 30% 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events 
[v.3.0] (http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/ctc.htm). It must 
be noted that the reduced LVFS values in this study associated with certain genetic background 
were in the „normal” range. According to several studies, normal-range or subclinical reduction 
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of LVFS in patients after anthracycline therapy might have prognostic value for late onset more 
serious cardiotoxicity (Kremer, van der Pal, 2002; Lipshultz, Alvarez, 2008). 
It is also important to note that some drugs used in the chemotherapy protocols, like vinca 
alkaloids and methotrexate, may also exert cardiotoxicity (Floyd et al., 2005; Simbre et al., 
2005). They are also substrates of ABCC1. These might also have contributed to the associations 
identified in our study. However, it is generally accepted that the cardiotoxic effect of 
anthracyclines considerably exceeds that of these other drugs. 
 
5. Conclusions 
 
Our results indicate that certain genotypes of the ABCC1 rs3743527 or rs246221 SNPs might 
influence the development of cardiotoxicity after anthracycline treatment in the studied patient 
population. It is well known that common genetic polymorphisms have weak effects; each one 
contributes only slightly to the susceptibility to a disease. The effect might be stronger, if 
genotype associations or haplotypes are investigated. According to these and earlier findings the 
ABCC1 transporter is important in limiting the anthracycline exposure of cardiomyocytes, and 
this protective mechanism may be influenced by genetic polymorphisms. Further studies with 
longer follow-up involving other genes are necessary to examine the exact genetic background of 
anthracycline induced late onset cardiomyopathy. Such studies are needed for establishing 
possible individualized chemotherapies. 
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Figure legends 
 
Figure 1. The genotyped SNPs and their position in the ABCC1 gene. The locations of the 
exonic SNPs are indicated in the schematic structure of the protein. Abbreviations: L, linker 
region; TMD, transmembrane domain; NBD, nucleotide binding domain. 
 
Figure 2. Left ventricular fractional shortening in the three time points in different 
genotypes of ABCC1 rs3743527 and rs246221 SNPs. Abbreviations: LVFS, Left ventricular 
fractional shortening; LVFS is indicated in boxplots, box is mean±95%CI, whiskers is 
mean±SD; * statistically significant differences. 
 
Figure 3. LVFS at three time points in rs3743527 and rs246221 genotype combinations. 
Abbreviations: LVFS, Left ventricular fractional shortening; group1, patients with genotype 
other than group2; group2, genotype rs3743527TT and rs246221TC/TT; LVFS is indicated in 
boxplots, box is mean±95%CI, whiskers is mean±SD; *statistically significant differences. 
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Table 1. 
Characteristics of the study population and all cases diagnosed with ALL between 1990 and 
2002 in Hungary in the hospitals included to the study from the Hungarian Paediatric Cancer 
Registry. 
Characteristics of patients Study population Whole population 
p 
value 
Number of patients 235 337  
Gender n (%)    
 Male 126 (54) 190 (56)  
 Female 109 (46) 147 (44) 0.6  
Age at diagnosis (mean ± SD, years (range))  5.7 ± 3.8 (1.2-18.0) 6.2 ± 4.1 (1.0-18.0) 0.1  
Risk group n (%)    
 LR 61 (26) 69 (20)  
 MR 155 (66) 231 (69)  
 HR 19 (8) 37 (11) 0.2  
Chemotherapy protocol n (%)    
 ALL BFM 90 (before 1995) 83 (35) 146 (44)  
 ALL BFM 95 (after 1995) 152 (65) 189 (56) 0.06 
Dexrazoxane usage n (%)    
 No 164 (70) 179 (70)  
 Yes 69 (30) 76 (30) 0.9  
Anthracycline dose (range, mg/m2)    
 During ALL BFM treatment 120-360 120-360  
 Including cumulative doses of those 
 treated for relapse 
120-840 120-840  
LVFS (mean ± SD, %)    
 At the diagnosis 39.8 ± 6.0 (n=133) n.d. a.  
 End of the treatment 39.0 ± 6.0 (n=173) n.d. a.  
 Latest ECHO 38.6 ± 5.2 (n=168) n.d. a.  
Time of the echocardiography from the 
 diagnosis (median, years) 
   
 End of the treatment (range) 2.0 (0.7-3.4) n.d. a.  
 Latest ECHO (range) 6.3 (2.4-13.7)  n.d. a.  
 
Abbreviations: ECHO, echocardiography; HR, high risk; LR, low risk; LVFS, left ventricular 
fractional shortening; MR, medium risk; n.d.a., no data available; SD, standard deviation 
 
Table 2. 
Genotyped SNPs and left ventricular fractional shortening in the three time points in different genotype groups. 
SNP 
Alleles 
on the 
forward 
strand 
Position 
according 
to NCBI 
Genome 
Build 36.3 
B a Function MAF 
Deviation 
from the 
HWE   
(χ2 test) 
LVFS time N all 
LVFS 
11 b 
SD N 11 
LVFS 
12 b 
SD N 12 
LVFS 
22 b 
SD N 22 p value 
rs215060 A/G 15984788 4 intron 0.14 0.51 
LVFS dg. 130 39.1 5.7 93 41.5 6.7 37 - -  0.1 
LVFS e.t. 168 38.8 6.0 118 39.6 5.9 50 - -  0.8 
LVFS l. 163 38.4 4.8 126 39.7 5.4 37 - -  0.2 
rs246219 C/T 15993136 5 intron 0.14 0.02 
LVFS dg. 128 39.2 6.0 91 40.9 6.2 37 - -  0.1 
LVFS e.t. 166 38.7 6.0 119 39.8 6.3 47 - -  1 
LVFS l. 161 38.3 5.1 123 39.1 5.1 38 - -  0.6 
rs246221 T/C 16045823 10 V275V 0.35 0.08 
LVFS dg. 132 40.0 6.0 57 39.3 6.1 65 42.5 5.0 10 0.1 
LVFS e.t. 171 39.4 6.5 69 38.4 5.6 84 40.0 6.4 18 0.2 
LVFS l. 164 38.4 4.8 62 38.5 5.2 86 40.7 5.6 16 0.027 
rs45511401 G/T 16080733 12 G671V 0.05 0.41 
LVFS dg. 129 39.7 6.2 114 41.3 5.2 15 - -  0.3 
LVFS e.t. 164 39.0 6.1 147 39.2 5.3 17 - -  1 
LVFS l. 155 38.7 5.0 140 38.1 5.8 15 - -  0.3 
rs4148358 C/T 16094676 13 intron 0.2 0.76 
LVFS dg. 130 39.6 6.1 80 40.2 6.0 50 - -  0.8 
LVFS e.t. 168 39.3 6.4 103 38.7 5.5 65 - -  0.3 
LVFS l. 162 38.5 5.3 112 38.5 4.5 50 - -  0.9 
rs11864374 A/G 16109386 14 intron 0.24 0.56 
LVFS dg. 129 39.0 6.1 72 41.1 5.7 49 39.3 6.8 8 0.1 
LVFS e.t. 165 39.0 5.7 95 39.0 6.5 57 39.4 6.6 13 0.5 
LVFS l. 162 38.5 4.6 97 38.3 5.2 53 41.5 6.1 12 0.2 
rs6416666 A/G 16121463 15 intron 0.07 0.28 
LVFS dg. 131 39.7 6.2 112 39.9 5.3 19 - -  0.7 
LVFS e.t. 170 39.1 6.0 144 38.5 6.4 26 - -  0.9 
LVFS l. 166 38.7 5.1 148 37.4 5.7 18 - -  0.3 
rs3743527 C/T 16143182 16 3' UTR 0.22 0.49 
LVFS dg. 131 39.7 5.6 79 40.1 7.1 43 38.5 4.5 9 0.5 
LVFS e.t. 168 39.5 5.8 103 39.3 6.4 54 34.0 4.4 11 0.001 
LVFS l. 161 38.7 4.9 108 38.9 5.1 47 35.3 3.6 6 0.2 
rs212097 A/G 16151630 16 3' UTR 0.47 0.43 
LVFS dg. 131 39.9 6.0 38 39.6 6.2 69 40.0 5.9 24 0.9 
LVFS e.t. 170 38.0 6.3 45 39.4 6.0 87 39.5 5.7 38 0.2 
LVFS l. 166 37.8 5.8 40 38.8 4.9 88 38.8 5.2 38 0.8 
 
a B: haplotype blocks determined by Haploview 4.1 using the HapMap data; b Mean LVFS of the patients in the different genotype groups: 11, 
homozygote for the frequent allele; 12, heterozygote; 22, homozygote for the rare allele. If there were not enough data for the rare 22 genotype 
groups, the 12 and 22 data were merged for the analysis. This is indicated with dashed line in column LVFS 22.; LVFS is indicated in mean %; 
HWE, Hardy-Weinberg equilibrium; LVFS, left ventricular fractional shortening; LVFS dg., LVFS at the time of diagnosis; LVFS e.t., LVFS at 
the end of the treatment; LVFS l., LVFS at the time of the latest echocardiography; N, number of patients in the genotype group; SD, standard 
deviation 
 
Table 3. 
LVFS in patients with rs3743527TT and rs246221TC or rs246221TT genotypes. 
LVFS time Patients 
involved 
LVFS 
group 1 a 
SD Number of 
patients in 
group 1 
LVFS 
group 2 b 
SD Number of 
patients in 
group 2 
p value 
LVFS dg. 118 39.8 6.2 122 38.5 4.5 9 0.4 
LVFS e.t. 167 39.4 6 157 34.0 4.4 11 0.001 
LVFS l. 166 38.7 4.9 156 35.6 4 5 0.1 
 
a group 1: patients with genotype other than group 2 patients; b group 2: patients with 
rs3743527TT and rs246221TC or TT genotypes; LVFS is indicated in mean %; LVFS, left 
ventricular fractional shortening; LVFS dg., LVFS at the time of diagnosis; LVFS e.t., LVFS 
at the end of the treatment; LVFS l., LVFS at the time of the latest echocardiography; SD, 
standard deviation 
 
 
